Brinton, L.T.; Sher, S.; Williams, K.; Canfield, D.; Orwick, S.; Wasmuth, R.; Cempre, C.; Skinner, J.; Lehman, A.; Blachly, J.S.;
et al. Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers 2020, 12, 1574.
https://doi.org/10.3390/cancers12061574
AMA Style
Brinton LT, Sher S, Williams K, Canfield D, Orwick S, Wasmuth R, Cempre C, Skinner J, Lehman A, Blachly JS,
et al. Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers. 2020; 12(6):1574.
https://doi.org/10.3390/cancers12061574
Chicago/Turabian Style
Brinton, Lindsey T., Steven Sher, Katie Williams, Daniel Canfield, Shelley Orwick, Ronni Wasmuth, Casey Cempre, Jordan Skinner, Amy Lehman, James S. Blachly,
and et al. 2020. "Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia" Cancers 12, no. 6: 1574.
https://doi.org/10.3390/cancers12061574
APA Style
Brinton, L. T., Sher, S., Williams, K., Canfield, D., Orwick, S., Wasmuth, R., Cempre, C., Skinner, J., Lehman, A., Blachly, J. S., Byrd, J. C., & Lapalombella, R.
(2020). Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers, 12(6), 1574.
https://doi.org/10.3390/cancers12061574